Fulgent Genetics, Inc.

NasdaqGM:FLGT Stock Report

Market Cap: US$659.4m

Fulgent Genetics Management

Management criteria checks 3/4

Fulgent Genetics' CEO is Ming Hsieh, appointed in May 2016, has a tenure of 7.83 years. total yearly compensation is $5.23M, comprised of 18.1% salary and 81.9% bonuses, including company stock and options. directly owns 29.28% of the company’s shares, worth $193.06M. The average tenure of the management team and the board of directors is 4 years and 3.1 years respectively.

Key information

Ming Hsieh

Chief executive officer

US$5.2m

Total compensation

CEO salary percentage18.1%
CEO tenure7.8yrs
CEO ownership29.3%
Management average tenure4yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Jan 25
Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy

Jan 09

Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot

Dec 20

I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease

Dec 14
I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease

Fulgent: Now Cheap Enough

Dec 06

CEO Compensation Analysis

How has Ming Hsieh's remuneration changed compared to Fulgent Genetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$168m

Sep 30 2023n/an/a

-US$64m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$5mUS$948k

US$143m

Sep 30 2022n/an/a

US$272m

Jun 30 2022n/an/a

US$392m

Mar 31 2022n/an/a

US$461m

Dec 31 2021US$6mUS$664k

US$507m

Sep 30 2021n/an/a

US$569m

Jun 30 2021n/an/a

US$493m

Mar 31 2021n/an/a

US$417m

Dec 31 2020US$248kUS$240k

US$214m

Sep 30 2020n/an/a

US$48m

Jun 30 2020n/an/a

US$3m

Mar 31 2020n/an/a

-US$459k

Dec 31 2019US$240kUS$240k

-US$411k

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$240kUS$240k

-US$6m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$5m

Dec 31 2017US$240kUS$240k

-US$3m

Compensation vs Market: Ming's total compensation ($USD5.23M) is above average for companies of similar size in the US market ($USD3.31M).

Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.


CEO

Ming Hsieh (67 yo)

7.8yrs

Tenure

US$5,233,873

Compensation

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...


Leadership Team

NamePositionTenureCompensationOwnership
Ming Hsieh
Chairman & CEO7.8yrsUS$5.23m29.28%
$ 193.1m
Jian Xie
COO & President5.9yrsUS$3.87m0.67%
$ 4.4m
Paul Kim
Chief Financial Officer8.2yrsUS$3.87m0.37%
$ 2.5m
Hanlin Gao
Chief Scientific Officer & Laboratory Director7.5yrsUS$3.75m2.83%
$ 18.7m
Natalie Prescott
General Counsel & Chief Privacy Officer1.8yrsno datano data
Doreen Ng
VP of Operations & Compliance and GM of Houston Office3.4yrsno datano data
Jakub Sram
Vice President of Business Development & Sales9.2yrsno datano data
Ellen Tsui
Vice President of Human Resources1.8yrsno datano data
Brandon Perthuis
Chief Commercial Officer4yrsno datano data
Lawrence Weiss
Chief Medical Officer2.8yrsno datano data
Ray Yin
President & Chief Scientific Officer of Fulgent Pharma1.3yrsno datano data

4.0yrs

Average Tenure

57yo

Average Age

Experienced Management: FLGT's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ming Hsieh
Chairman & CEO7.8yrsUS$5.23m29.28%
$ 193.1m
Regina Groves
Independent Non-Employee Director1.2yrsno datano data
Linda Marsh
Independent Director4.6yrsUS$279.24k0.0046%
$ 30.5k
Michael Nohaile
Independent Non-Employee Director1.6yrsUS$726.47kno data

3.1yrs

Average Tenure

66yo

Average Age

Experienced Board: FLGT's board of directors are considered experienced (3.1 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.